Back to top

Research Daily

Wednesday, June 29, 2016

In today's long line-up of research reports, we want to highlight Amgen (AMGN), Kraft Heinz (KHC), and UPS (UPS)

Amgen shares have been weak lately given the overall tough environment for the space, but this Zack Rank # 2 (Buy) biotech major  is well-positioned for growth with several blockbuster drugs in its portfolio. (Full research report on AMGN)

Kraft Heinz share have benefited from business consolidation and cost saving measures that are helping its margins. The analyst likes this buy-rated stock's impressive portfolio of packaged food and beverage products. (Full research report on KHC)

There is a reason why UPS shares have outperformed t FedEx (FDX), which you can see in the research report on UPS .

Other reports today include Barclays (BCS), Gilead (GILD) and Expedia (EXPE).

You can find all of today's stock research reports here.

Note: Sheraz Mian regularly provides earnings analysis on and appears frequently in the print and electronic media. He also provides weekly commentary to Zacks Premium subscribers and manages the Zacks Focus List and Top 10 portfolios. If you want an email notification each time Sheraz publishes a new article, please click here

Featured Reports

Gilead's (GILD) Drug Gains FDA Approval

Gilead has received a boost with the FDA approving the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus infection.

New Upgrades

New Downgrades

Dr Pepper (DPS) to Face Headwinds in Q2

The covering analyst believes currency headwinds, possible softer fountain food-service volumes, higher health and welfare insurance costs will hurt profits in the second quarter.n